Karyopharm Therapeutics | KPTI - 营业利润



金融业
股票价格
USD
资产
USD 96.23M
现金及等价物
USD 37.67M
销售成本
USD 37.43M
流动资产
USD 89.75M
流动负债
USD 87.16M
债务
USD 264.09M
股息收益率
0
EBIT
USD -26.28M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -0.15
股本和储备
USD -269.26M
销售毛利
USD -30.78M
债务利息支出
USD 11.38M
利息收入
USD -0.15
贷款资金
USD -0.93
市值
USD 878M
净收入
USD -30.78M
营业费用
USD 61.82M
营业利润
USD -31.28M
普通股股本
USD 13K
税前利润
USD -30.89M
销售收入
USD 30.54M
销售和管理费用
USD 27.19M
股票
USD 3.97M
贸易债权人
USD 5.39M
应收帐款人
USD 31.78M


营业利润 更改 日
AbbVie USD 5.81B 1.23B 2025-12
Abbott USD 2.25B 73M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Incyte USD 383.88M 47.43M 2025-12
J&J USD 5.59B 1.81B 2025-12
Karyopharm Therapeutics USD -31.28M 5M 2024-12
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD 6.24B 318M 2025-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Novartis USD 4.06B 437M 2025-12
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Takeda JPY 168.82B 479.89B 2025-12
Tectonic Therapeutic USD -21.52M 374K 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Xencor USD -53.63M 6.11M 2025-12